UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 4.336

Sortiert nach

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

The New England journal of medicine, 2019-07, Vol.381 (4), p.317-327

2019

Volltextzugriff (PDF)

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Science (American Association for the Advancement of Science), 2007-05, Vol.316 (5827), p.1039-1043

2007

Volltextzugriff (PDF)

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study

Cancer science, 2020-02, Vol.111 (2), p.513-527

2020

Volltextzugriff (PDF)

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review

Cancers, 2021-04, Vol.13 (7), p.1647

2021

Volltextzugriff (PDF)

Multi‐biomarker panel prediction model for diagnosis of pancreatic cancer

Journal of hepato-biliary-pancreatic sciences, 2023-01, Vol.30 (1), p.122-132

2023

Volltextzugriff (PDF)

Neuroprotective Effect of Cudrania tricuspidata Fruit Extracts on Scopolamine-Induced Learning and Memory Impairment

International journal of molecular sciences, 2020-12, Vol.21 (23), p.9202

2020

Volltextzugriff (PDF)

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer

Technology in cancer research & treatment, 2021, Vol.20, p.15330338211062324-15330338211062324

2021

Volltextzugriff (PDF)

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation

Therapeutic advances in gastroenterology, 2023-01, Vol.16, p.17562848231170484-17562848231170484

2023

Volltextzugriff (PDF)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

Therapeutic advances in medical oncology, 2021, Vol.13, p.1758835921992992-1758835921992992

2021

Volltextzugriff (PDF)

Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach

Oncotarget, 2017-06, Vol.8 (26), p.42761-42771

2017

Volltextzugriff (PDF)

Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-11, Vol.25 (33), p.5233-5239

2007

Volltextzugriff (PDF)

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

Molecular cancer therapeutics, 2017-01, Vol.16 (1), p.228-238

2017

Volltextzugriff (PDF)

Intrathecal RGS4 Inhibitor, CCG50014, Reduces Nociceptive Responses and Enhances Opioid-Mediated Analgesic Effects in the Mouse Formalin Test

Anesthesia and analgesia, 2015-03, Vol.120 (3), p.671-677

2015

Volltextzugriff (PDF)

Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211038478-17588359211038478

2021

Volltextzugriff (PDF)

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group

Therapeutic advances in medical oncology, 2019-08, Vol.11, p.1758835919871126-1758835919871126

2019

Volltextzugriff (PDF)

Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer

Therapeutic advances in gastroenterology, 2022, Vol.15, p.175628482211176-17562848221117638

2022

Volltextzugriff (PDF)

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Nature medicine, 2018-09, Vol.24 (9), p.1449-1458

2018

Volltextzugriff (PDF)

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

Cancer, 2007-04, Vol.109 (8), p.1561-1569

2007

Volltextzugriff (PDF)

Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma

Proteomics (Weinheim), 2012-12, Vol.12 (23-24), p.3590-3597

2012

Volltextzugriff (PDF)

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Nature medicine, 2020-06, Vol.26 (6), p.878-885

2020

Volltextzugriff (PDF)

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Therapeutic advances in medical oncology, 2020, Vol.12, p.175883592096584-1758835920965842

2020

Volltextzugriff (PDF)

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

Journal of clinical oncology, 2012-05, Vol.30 (13), p.1513-1518

2012

Volltextzugriff (PDF)

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920926796

2020

Volltextzugriff (PDF)

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Journal of clinical oncology, 2021-04, Vol.39 (10), p.1108-1118

2021

Volltextzugriff (PDF)

1 – 25 von 4.336

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.873)
Mit Volltextzugriff
(4.113)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.737)
Life Sciences & Biomedicine
(2.114)
Humans
(1.393)
Female
(968)
Male
(935)
Middle Aged
(756)
Aged
(646)
Adult
(607)
Oncology
(409)
Technology
(401)
Physical Sciences
(357)
Original
(326)
Retrospective Studies
(324)
Animals
(300)
Treatment Outcome
(273)
Biological And Medical Sciences
(269)
Patients
(256)
Science & Technology - Other Topics
(247)
Aged, 80 And Over
(241)
Risk Factors
(241)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review

Multi‐biomarker panel prediction model for diagnosis of pancreatic cancer

Neuroprotective Effect of Cudrania tricuspidata Fruit Extracts on Scopolamine-Induced Learning and Memory Impairment

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach

Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

Intrathecal RGS4 Inhibitor, CCG50014, Reduces Nociceptive Responses and Enhances Opioid-Mediated Analgesic Effects in the Mouse Formalin Test

Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group

Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Suchergebnisse filtern